AP2395A - New composition containing quinoline compounds. - Google Patents

New composition containing quinoline compounds.

Info

Publication number
AP2395A
AP2395A AP2006003674A AP2006003674A AP2395A AP 2395 A AP2395 A AP 2395A AP 2006003674 A AP2006003674 A AP 2006003674A AP 2006003674 A AP2006003674 A AP 2006003674A AP 2395 A AP2395 A AP 2395A
Authority
AP
ARIPO
Prior art keywords
composition containing
new composition
quinoline compounds
containing quinoline
compounds
Prior art date
Application number
AP2006003674A
Other languages
English (en)
Other versions
AP2006003674A0 (en
Inventor
Karl Jansson
Tomas Fristedt
Hans Wannman
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of AP2006003674A0 publication Critical patent/AP2006003674A0/xx
Application granted granted Critical
Publication of AP2395A publication Critical patent/AP2395A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2006003674A 2004-02-06 2005-02-04 New composition containing quinoline compounds. AP2395A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0400235A SE0400235D0 (sv) 2004-02-06 2004-02-06 New composition containing quinoline compounds
PCT/EP2005/050485 WO2005074899A2 (en) 2004-02-06 2005-02-04 New compositions containing quinoline compounds

Publications (2)

Publication Number Publication Date
AP2006003674A0 AP2006003674A0 (en) 2006-08-31
AP2395A true AP2395A (en) 2012-04-10

Family

ID=31885235

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003674A AP2395A (en) 2004-02-06 2005-02-04 New composition containing quinoline compounds.

Country Status (25)

Country Link
US (1) US7589208B2 (es)
EP (1) EP1720531B1 (es)
JP (1) JP4864724B2 (es)
KR (3) KR20120062029A (es)
CN (1) CN1980669B (es)
AP (1) AP2395A (es)
AT (1) ATE505186T1 (es)
AU (1) AU2005210174B2 (es)
BR (1) BRPI0506906B1 (es)
CA (1) CA2552463C (es)
CY (1) CY1111697T1 (es)
DE (1) DE602005027445D1 (es)
DK (1) DK1720531T3 (es)
ES (1) ES2364754T3 (es)
IL (1) IL176255A (es)
NO (1) NO337235B1 (es)
NZ (1) NZ548469A (es)
PL (1) PL1720531T3 (es)
PT (1) PT1720531E (es)
RU (1) RU2339622C2 (es)
SE (1) SE0400235D0 (es)
SI (1) SI1720531T1 (es)
UA (1) UA90463C2 (es)
WO (1) WO2005074899A2 (es)
ZA (1) ZA200605619B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060446A1 (fr) 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
EA011862B1 (ru) * 2004-03-24 2009-06-30 Актавис Груп Хф. Композиции рамиприла
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
NZ567088A (en) 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
AU2013201426B2 (en) * 2005-12-28 2016-06-02 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2016219571B2 (en) * 2005-12-28 2018-03-15 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
CN101878041A (zh) * 2007-11-27 2010-11-03 大原药品工业株式会社 颗粒制剂的制造方法
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8354428B2 (en) * 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
KR20110048571A (ko) * 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
BRPI0923155A2 (pt) * 2008-12-05 2018-10-23 Abraxis Bioscience Llc scfcs de ligação a sparc
DE102008064379A1 (de) * 2008-12-22 2010-07-15 Siemens Aktiengesellschaft Magnetspulenanordnung mit festen und beweglichen Spulen
SI2408750T1 (sl) 2009-03-20 2015-11-30 Vertex Pharmaceuticals Incorporated Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
JP5503192B2 (ja) * 2009-06-03 2014-05-28 大原薬品工業株式会社 生理活性物質含有粒子の製造方法
JP2012530701A (ja) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
EP2523668A1 (en) 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
JP2013516459A (ja) * 2010-01-20 2013-05-13 カディラ・ヘルスケア・リミテッド ピタバスタチン及び医薬として許容可能なそれらの塩の製造方法
DK2542079T3 (da) 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
CA2791711A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
SG183512A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
US9394324B2 (en) * 2010-03-23 2016-07-19 Vifor (International) Ag Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
EP2590653A4 (en) 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2012050500A1 (en) 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
WO2012163938A1 (de) 2011-05-31 2012-12-06 Vifor (International) Ag Fe(iii)-2,4-dioxo-1-carbonyl-komplexverbindungen zur behandlung und prophylaxe von eisenmangelerscheinungen und eisenmangelanämien
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
CA2891572A1 (en) * 2012-12-21 2014-06-26 Vifor (International) Ag Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
US20160038435A1 (en) 2013-03-14 2016-02-11 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
JP6647287B2 (ja) 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
MX379401B (es) 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
KR20180065223A (ko) 2016-12-07 2018-06-18 순천향대학교 산학협력단 천식의 치료 또는 완화용 약학 조성물
EP3836912B1 (en) 2018-08-15 2024-05-01 Pharmacyl AB Combinations of substituted benzamides and 5-asa agents
AU2019322187A1 (en) 2018-08-15 2021-03-25 Pharmacyl Ab Substituted benzamides and their use in therapy
CN115836056A (zh) * 2020-05-21 2023-03-21 Stemsynergy疗法有限责任公司 Notch抑制剂及其用途
BR112023000892A2 (pt) 2020-07-23 2023-02-07 Univ Erasmus Med Ct Rotterdam Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor
ES3057099T3 (en) 2021-01-18 2026-02-26 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547511A (en) * 1981-03-03 1985-10-15 Aktiebolaget Leo Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith
US5716638A (en) * 1994-06-22 1998-02-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composition for applying active substances to or through the skin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
US5077851A (en) * 1989-02-27 1992-01-07 Guma Juan M Method and apparatus for treating corded fabrics
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
CZ288545B6 (cs) 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
US5965560A (en) * 1996-04-30 1999-10-12 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
SK286420B6 (sk) * 1997-09-15 2008-09-05 The Procter & Gamble Company Zlúčenina so štruktúrou chinolónu, farmaceutický prostriedok s jej obsahom a jej použitie
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547511A (en) * 1981-03-03 1985-10-15 Aktiebolaget Leo Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith
US5716638A (en) * 1994-06-22 1998-02-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composition for applying active substances to or through the skin

Also Published As

Publication number Publication date
BRPI0506906A (pt) 2007-05-29
KR20130012084A (ko) 2013-01-31
RU2339622C2 (ru) 2008-11-27
AU2005210174A1 (en) 2005-08-18
ATE505186T1 (de) 2011-04-15
CN1980669B (zh) 2011-11-30
DK1720531T3 (da) 2011-08-01
PL1720531T3 (pl) 2011-09-30
WO2005074899A2 (en) 2005-08-18
KR20120062029A (ko) 2012-06-13
ES2364754T3 (es) 2011-09-13
UA90463C2 (ru) 2010-05-11
NO20063931L (no) 2006-09-04
KR101189557B1 (ko) 2012-10-12
ZA200605619B (en) 2007-11-28
KR101457463B1 (ko) 2014-11-04
AU2005210174B2 (en) 2010-10-07
EP1720531B1 (en) 2011-04-13
KR20060130191A (ko) 2006-12-18
CA2552463C (en) 2013-05-14
DE602005027445D1 (de) 2011-05-26
CN1980669A (zh) 2007-06-13
BRPI0506906B1 (pt) 2018-05-15
CA2552463A1 (en) 2005-08-18
NO337235B1 (no) 2016-02-15
SI1720531T1 (sl) 2011-08-31
US20050192315A1 (en) 2005-09-01
AP2006003674A0 (en) 2006-08-31
HK1105866A1 (en) 2008-02-29
SE0400235D0 (sv) 2004-02-06
US7589208B2 (en) 2009-09-15
NZ548469A (en) 2010-05-28
IL176255A0 (en) 2006-10-05
PT1720531E (pt) 2011-06-27
JP2007520529A (ja) 2007-07-26
JP4864724B2 (ja) 2012-02-01
RU2006132070A (ru) 2008-03-20
IL176255A (en) 2011-11-30
EP1720531A2 (en) 2006-11-15
WO2005074899A3 (en) 2007-04-19
CY1111697T1 (el) 2015-10-07

Similar Documents

Publication Publication Date Title
AP2395A (en) New composition containing quinoline compounds.
IL208963A0 (en) Substituted quinoline compounds
GB0400812D0 (en) Novel compounds
EP1718638A4 (en) NEW COMPOUNDS
GB0402140D0 (en) Novel compounds
GB0402496D0 (en) Novel compounds
GB0402357D0 (en) Novel compounds
GB0403819D0 (en) New compounds
EP1805132A4 (en) NEW COMPOUNDS
GB0427403D0 (en) Novel compounds I
GB0402355D0 (en) Novel compounds
GB0402812D0 (en) Novel compounds
GB0418015D0 (en) New compounds
ZA200605575B (en) Substituted quinoline compounds
GB0404105D0 (en) Novel compounds
GB0402380D0 (en) Novel compounds
GB0428061D0 (en) Novel Quinoline Compounds
HUP0401468D0 (en) New compounds
GB0420169D0 (en) New compounds
HUP0401467D0 (en) New compounds
GB0402114D0 (en) Novel compounds
GB0400699D0 (en) Novel compounds
GB0402134D0 (en) Novel compounds
GB0400460D0 (en) Novel compounds
GB0402142D0 (en) Novel compounds